{"id":3335,"date":"2026-02-07T14:38:40","date_gmt":"2026-02-07T14:38:40","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/3335\/"},"modified":"2026-02-07T14:38:40","modified_gmt":"2026-02-07T14:38:40","slug":"novo-nordisk-lowers-sales-profits-forecast-as-wegovy-faces-competition","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/3335\/","title":{"rendered":"Novo Nordisk lowers sales, profits forecast as Wegovy faces competition"},"content":{"rendered":"

Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of Wegovy faces growing competition in the obesity market.<\/p>\n

The Danish pharma giant said it expects sales to decrease in the range of 5% to 13% in 2026, more than the 3% decrease forecasted by analysts surveyed by Visible Alpha. Novo also expects operating profits to decrease in the range of 5% to 13%, while analysts predicted a 5% decrease.<\/p>\n

\t\t\t\"\"\t\t<\/p>\n

\t\t\t\t\"\"\/
\n\t\t\t\tSTAT Plus: With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market<\/a><\/p>\n

Shares of Novo plummeted more than 14% as of midday Tuesday. The company was scheduled to report earnings on Wednesday but released these results early.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk on Tuesday said it expects sales and profits to decline this year, as the maker of…\n","protected":false},"author":2,"featured_media":3336,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2759,272,357,358,359,280],"class_list":{"0":"post-3335","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-biotechnology","9":"tag-novo-nordisk","10":"tag-obesity","11":"tag-pharmaceuticals","12":"tag-stat","13":"tag-weight-loss"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/3335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=3335"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/3335\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/3336"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=3335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=3335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=3335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}